CTN 010
Alternative Names: CTN-010Latest Information Update: 03 Sep 2024
Price :
$50 *
At a glance
- Originator Centenaire Biosciences
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atopic dermatitis
Most Recent Events
- 29 Aug 2024 CTN 010 is available for licensing as of 29 Aug 2024. https://www.ctnbio.com/partnering (Centenaire Biosciences website, August 2024)
- 29 Aug 2024 Preclinical trials in Atopic dermatitis in South Korea (Parenteral), prior to August 2024 (Centenaire Biosciences pipeline, August 2024)